间断给药能否优化利奈唑胺治疗耐药性结核病的长期方案？
Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?
机构信息
Tuberculosis and Chest Service, Department of Health, Hong Kong SAR, China.
出版信息
Antimicrob Agents Chemother. 2013 Jul;57(7):3445-9. doi: 10.1128/AAC.00388-13. Epub 2013 May 6.
Abstract
We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until ≥ 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.
摘要
我们评估了利奈唑胺治疗方案，在连续 10 例广泛耐药或氟喹诺酮类耐药耐多药结核患者中，在痰培养结果和药物耐受情况的指导下，初始剂量为 800mg 每日一次，持续 1-4 个月，然后根据情况转为 1200mg 每周三次，持续至少 1 年。在个体化优化方案的基础上，同时加用利奈唑胺。所有患者均获得稳定治愈，贫血得到纠正，神经病变稳定、改善或避免了药物的不良反应。血清利奈唑胺浓度谱优化得更好。
相似文献
1
Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?间断给药能否优化利奈唑胺治疗耐药性结核病的长期方案？
Antimicrob Agents Chemother. 2013 Jul;57(7):3445-9. doi: 10.1128/AAC.00388-13. Epub 2013 May 6.
2
Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.每日半剂量利奈唑胺治疗难治性耐多药结核病。
Int J Antimicrob Agents. 2009 Jan;33(1):92-3. doi: 10.1016/j.ijantimicag.2008.06.014. Epub 2008 Sep 11.
3
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.每日300毫克利奈唑胺剂量用于治疗难治性耐多药和广泛耐药结核病。
J Antimicrob Chemother. 2009 Aug;64(2):388-91. doi: 10.1093/jac/dkp171. Epub 2009 May 25.
4
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.关于《每日300毫克利奈唑胺治疗难治性耐多药和广泛耐药结核病》的评论
J Antimicrob Chemother. 2009 Nov;64(5):1119; author reply 1119-20. doi: 10.1093/jac/dkp291. Epub 2009 Aug 8.
5
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.每日300毫克利奈唑胺剂量用于治疗难治性耐多药和广泛耐药结核病——作者回应
J Antimicrob Chemother. 2009 Nov;64(5):1119-20. doi: 10.1093/jac/dkp344. Epub 2009 Sep 10.
6
Linezolid in the treatment of MDR-TB: a retrospective clinical study.利奈唑胺治疗耐多药结核病：一项回顾性临床研究。
Int J Tuberc Lung Dis. 2012;16(3):358-63. doi: 10.5588/ijtld.11.0493.
7
[The analysis of clinical data about the treatment of linezolid against tuberculosis].[利奈唑胺治疗结核病的临床数据分析]
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Aug;36(8):601-3.
8
Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological and imaging response of lung tuberculosis to specific treatment. Which role for linezolid?肺结核的病变模式增加：一项对肺结核特定治疗的临床、微生物学和影像学缓慢反应的观察性研究。利奈唑胺的作用是什么？
Braz J Infect Dis. 2009 Aug;13(4):297-303. doi: 10.1590/s1413-86702009000400012.
9
Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.每日半剂量利奈唑胺治疗难治性耐多药结核病患者的疗效及耐受性
J Antimicrob Chemother. 2006 Sep;58(3):701-4. doi: 10.1093/jac/dkl298. Epub 2006 Jul 19.
10
Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.利奈唑胺治疗耐药结核病的系统评价和荟萃分析。
Int J Tuberc Lung Dis. 2012 Apr;16(4):447-54. doi: 10.5588/ijtld.11.0451.
引用本文的文献
1
Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis.低剂量利奈唑胺治疗耐多药结核病患者
Open Forum Infect Dis. 2022 Oct 5;9(12):ofac500. doi: 10.1093/ofid/ofac500. eCollection 2022 Dec.
2
Complicated Case of Multidrug-Resistant Tuberculosis with Multiple Comorbidities, Successfully Treated After Several Treatment Modifications.多重耐药结核病合并多种并发症的复杂病例，经多次治疗调整后成功治愈。
Clin Med Insights Circ Respir Pulm Med. 2022 Dec 15;16:11795484221142468. doi: 10.1177/11795484221142468. eCollection 2022.
3
Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis.利奈唑胺暴露与耐多药结核病患者的血液学毒性相关。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0040822. doi: 10.1128/aac.00408-22. Epub 2022 Aug 2.
4
Successful treatment of linezolid-induced severe lactic acidosis with continuous venovenous hemodiafiltration: A case report.连续性静脉-静脉血液透析滤过成功治疗利奈唑胺所致严重乳酸酸中毒：一例报告
Saudi Pharm J. 2022 Feb;30(2):108-111. doi: 10.1016/j.jsps.2021.12.021. Epub 2021 Dec 31.
5
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.间断利奈唑胺联合贝达喹啉和德拉马尼治疗方案在小鼠结核病模型中保持疗效并降低毒性。
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.01178-20.
6
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.药物相关不良事件在耐多药结核病治疗中的作用：一项个体患者数据荟萃分析。
Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17.
7
Linezolid for drug-resistant pulmonary tuberculosis.利奈唑胺用于耐药性肺结核
Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD012836. doi: 10.1002/14651858.CD012836.pub2.
8
Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.利奈唑胺在南非耐药结核病合并高发 HIV 合并感染患者中的药代动力学。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02164-18. Print 2019 Mar.
9
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素：一项个体患者数据荟萃分析。
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
10
New anti-tuberculosis drugs and regimens: 2015 update.新型抗结核药物与治疗方案：2015年更新
ERJ Open Res. 2015 May 6;1(1). doi: 10.1183/23120541.00010-2015. eCollection 2015 May.
本文引用的文献
1
Linezolid for treatment of chronic extensively drug-resistant tuberculosis.利奈唑胺治疗慢性广泛耐药结核病。
N Engl J Med. 2012 Oct 18;367(16):1508-18. doi: 10.1056/NEJMoa1201964.
2
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.利奈唑胺方案治疗耐多药结核病和广泛耐药结核病的疗效、安全性和耐受性：系统评价和荟萃分析。
Eur Respir J. 2012 Dec;40(6):1430-42. doi: 10.1183/09031936.00022912. Epub 2012 Apr 10.
3
Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.每日 300 毫克利奈唑胺治疗耐多药和广泛耐药结核病：51 例患者的更新分析。
J Antimicrob Chemother. 2012 Jun;67(6):1503-7. doi: 10.1093/jac/dks078. Epub 2012 Mar 8.
4
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.生物标志物辅助剂量选择用于结核治疗的 PNU-100480 早期开发的安全性和疗效。
Antimicrob Agents Chemother. 2011 Feb;55(2):567-74. doi: 10.1128/AAC.01179-10. Epub 2010 Nov 15.
5
Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.健康志愿者单次使用 PNU-100480 后的药代动力学和全血抗结核分枝杆菌杀菌活性。
J Infect Dis. 2010 Sep 1;202(5):745-51. doi: 10.1086/655471.
6
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.每日300毫克利奈唑胺剂量用于治疗难治性耐多药和广泛耐药结核病。
J Antimicrob Chemother. 2009 Aug;64(2):388-91. doi: 10.1093/jac/dkp171. Epub 2009 May 25.
7
Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.在小鼠模型中，恶唑烷酮类药物PNU-100480相对于利奈唑胺具有有前景的抗结核活性。
Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9. doi: 10.1128/AAC.01182-08. Epub 2008 Dec 15.
8
Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.恶唑烷酮类对哺乳动物线粒体蛋白质合成的抑制作用。
Antimicrob Agents Chemother. 2006 Jun;50(6):2042-9. doi: 10.1128/AAC.01411-05.
9
Peripheral neuropathy associated with prolonged use of linezolid.与长期使用利奈唑胺相关的周围神经病变。
Lancet Infect Dis. 2004 Aug;4(8):528-31. doi: 10.1016/S1473-3099(04)01109-0.
10
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.分枝杆菌感染治疗中的药代动力学和药效学问题。
Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):243-55. doi: 10.1007/s10096-004-1109-5. Epub 2004 Mar 13.
Zotero 插件